^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGF3 mutation

    i
    Other names: FGF3, Fibroblast Growth Factor 3, V-INT2 Murine Mammary Tumor Virus Integration Site Oncogene Homolog, Murine Mammary Tumor Virus Integration Site 2, Heparin-Binding Growth Factor 3, INT-2 Proto-Oncogene Protein, Proto-Oncogene Int-2, Oncogene INT2, HBGF-3, INT2
    Entrez ID:
    2248
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    3years
    [VIRTUAL] The landscape of the related genes to immunotherapy hyperprogression in Chinese patients with solid tumors (AACR 2021)
    This study suggests that a small subset of most tumor types have about 8% immunotherapy hyperprogression related genes mutations.
    Clinical • IO biomarker
    |
    CCND1 (Cyclin D1) • MDM2 (E3 ubiquitin protein ligase) • FGF19 (Fibroblast growth factor 19) • CDK4 (Cyclin-dependent kinase 4) • FGF3 (Fibroblast growth factor 3) • MDM4 (The mouse double minute 4) • FGF4 (Fibroblast growth factor 4)
    |
    FGF3 mutation • MDM2 mutation • CDK4 mutation
    over3years
    ESR1 Genetic Alterations and their Association with Clinicopathologic Characteristics in Advanced Breast Cancer: A single Academic Institution Experience. (PubMed, Hum Pathol)
    In comparison to ESR1-non-mutated ER-positive cases, ESR1-mutated cases demonstrated significantly higher percentage of tumor cells with ER and PR expression, an increased tendency for overall distant metastasis and liver metastasis, higher frequency of FGF3/4/19 mutations, lower frequency of TP53 mutation, but no difference in overall survival and metastatic/recurrent intervals. In conclusion, our findings suggest that development of ESR1 mutations are selected for under the influence of estrogen deprivation, and a positive correlation between ESR1 mutations and ER protein expression may exist.
    Journal • Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • FGF3 (Fibroblast growth factor 3)
    |
    HER-2 positive • TP53 mutation • ER positive • HER-2 amplification • HER-2 mutation • ER mutation • ER Y537S • ER D538G • FGF3 mutation
    |
    FoundationOne® CDx